Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Tirzepatide (Mounjaro/Zepbound) is a dual GLP-1 and GIP receptor agonist it activates two separate hormonal pathways simultaneously
The Takeaway While both Novo and Lilly have multi-year regulatory head-starts and are now rapidly becoming part of the zeitgeist around treating obesity, Regenerons angle of addressing muscle loss could help set it apart from other GLP-1 hopefuls and even incumbents by leading to improved long-term outcomes.
It is important to note that this mechanism, while biologically plausible, is not yet validated by large-scale controlled trials, and individual results vary considerably depending on baseline melanin levels, skin type, and dosage
Mechanism of action Semaglutide is a glucagon-like peptide-1 receptor agonist
